Strategy for preventing hepatitis B reactivation in patients with resolved hepatitis B virus infection after rituximab-containing chemotherapy

Authors


  • Potential conflict of interest: Dr. Kusumoto has received research funding from Chugai Pharmaceutical Co. Ltd. and honoraria from Chugai Pharmaceutical Co. Ltd., Bristol-Myers Squibb, Zenyaku Kogyo, and Abbott. He is on the speakers' bureau for Chugai, Abbott, Zenyaku Kogyu, and Bristol-Myers Squibb. Dr. Tanaka has received research funding from Chugai Pharmaceutical Co. Ltd. and Bristol-Myers Squibb and has received honoraria from Chugai Pharmaceutical Co. Ltd., Bristol-Myers Squibb, Zenyaku Kogyo, and Abbott. He is on the speakers' bureau for Bristol-Myers Squibb, Chugai, Abbott, and Zenyaku Kogyo. Dr. Mizokami has received honoraria from and is on the speakers' bureau for Chugai Pharmaceutical Co. Ltd. and Abbott. Dr. Ueda has received research funding from Chugai Pharmaceutical Co. Ltd. and Kyowa Hakko Kirin Co. Ltd.

No abstract is available for this article.

Ancillary